Your browser doesn't support javascript.
loading
mRNA-HPV vaccine encoding E6 and E7 improves therapeutic potential for HPV-mediated cancers via subcutaneous immunization.
Lee, Seonghyun; Yoon, Hyunho; Hong, Seol Hee; Kwon, Sung Pil; Hong, Jung Joo; Kwak, Hye Won; Park, Hyeong-Jun; Yoo, Soyeon; Bae, Seo-Hyeon; Park, Hyo-Jung; Lee, Jisun; Bang, Yoo-Jin; Lee, Yu-Sun; Kim, Jae-Yong; Yoon, Subin; Roh, Gahyun; Cho, Youngran; Kim, Yongkwan; Kim, Daegeun; Park, Sang-In; Kim, Do-Hyung; Lee, Sowon; Oh, Ayoung; Ha, Dahyeon; Lee, Soo-Yeon; Park, Misung; Hwang, Eun-Ha; Bae, Gyuseo; Jeon, Eunsu; Park, Sung Hyun; Choi, Won Seok; Oh, Ho Rim; Kim, In Woo; Youn, Hyewon; Keum, Gyochang; Bang, Eun-Kyoung; Rhee, Joon Haeng; Lee, Shee Eun; Nam, Jae-Hwan.
Afiliación
  • Lee S; Department of Medical and Biological Sciences, The Catholic University of Korea, Bucheon, Gyeonggi-do, South Korea.
  • Yoon H; BK21 four Department of Biotechnology, The Catholic University of Korea, Bucheon, Gyeonggi-do, South Korea.
  • Hong SH; Department of Medical and Biological Sciences, The Catholic University of Korea, Bucheon, Gyeonggi-do, South Korea.
  • Kwon SP; BK21 four Department of Biotechnology, The Catholic University of Korea, Bucheon, Gyeonggi-do, South Korea.
  • Hong JJ; National Immunotherapy Innovation Center, Hwasun-gun, Jeonnam, South Korea.
  • Kwak HW; Department of Pharmacology and Dental Therapeutics, School of Dentistry, Chonnam National University, Gwangju, South Korea.
  • Park HJ; Brain Science Institute, Korea Institute of Science and Technology, Seoul, South Korea.
  • Yoo S; National Primate Research Center, Korea Research Institute of Bioscience and Biotechnology (KRIBB), Cheongju, Chungcheongbuk-do, South Korea.
  • Bae SH; KRIBB School of Bioscience, Korea University of Science & Technology (UST), Daejeon, South Korea.
  • Park HJ; R&D Research Center, SML Biopharm, Gwangmyeong, Gyeonggi-do, South Korea.
  • Lee J; R&D Research Center, SML Biopharm, Gwangmyeong, Gyeonggi-do, South Korea.
  • Bang YJ; Brain Science Institute, Korea Institute of Science and Technology, Seoul, South Korea.
  • Lee YS; Department of Medical and Biological Sciences, The Catholic University of Korea, Bucheon, Gyeonggi-do, South Korea.
  • Kim JY; BK21 four Department of Biotechnology, The Catholic University of Korea, Bucheon, Gyeonggi-do, South Korea.
  • Yoon S; Department of Medical and Biological Sciences, The Catholic University of Korea, Bucheon, Gyeonggi-do, South Korea.
  • Roh G; BK21 four Department of Biotechnology, The Catholic University of Korea, Bucheon, Gyeonggi-do, South Korea.
  • Cho Y; Department of Medical and Biological Sciences, The Catholic University of Korea, Bucheon, Gyeonggi-do, South Korea.
  • Kim Y; Department of Medical and Biological Sciences, The Catholic University of Korea, Bucheon, Gyeonggi-do, South Korea.
  • Kim D; R&D Research Center, SML Biopharm, Gwangmyeong, Gyeonggi-do, South Korea.
  • Park SI; Department of Medical and Biological Sciences, The Catholic University of Korea, Bucheon, Gyeonggi-do, South Korea.
  • Kim DH; BK21 four Department of Biotechnology, The Catholic University of Korea, Bucheon, Gyeonggi-do, South Korea.
  • Lee S; Department of Medical and Biological Sciences, The Catholic University of Korea, Bucheon, Gyeonggi-do, South Korea.
  • Oh A; R&D Research Center, SML Biopharm, Gwangmyeong, Gyeonggi-do, South Korea.
  • Ha D; Department of Medical and Biological Sciences, The Catholic University of Korea, Bucheon, Gyeonggi-do, South Korea.
  • Lee SY; BK21 four Department of Biotechnology, The Catholic University of Korea, Bucheon, Gyeonggi-do, South Korea.
  • Park M; Department of Medical and Biological Sciences, The Catholic University of Korea, Bucheon, Gyeonggi-do, South Korea.
  • Hwang EH; BK21 four Department of Biotechnology, The Catholic University of Korea, Bucheon, Gyeonggi-do, South Korea.
  • Bae G; Department of Medical and Biological Sciences, The Catholic University of Korea, Bucheon, Gyeonggi-do, South Korea.
  • Jeon E; BK21 four Department of Biotechnology, The Catholic University of Korea, Bucheon, Gyeonggi-do, South Korea.
  • Park SH; R&D Research Center, SML Biopharm, Gwangmyeong, Gyeonggi-do, South Korea.
  • Choi WS; R&D Research Center, SML Biopharm, Gwangmyeong, Gyeonggi-do, South Korea.
  • Oh HR; R&D Research Center, SML Biopharm, Gwangmyeong, Gyeonggi-do, South Korea.
  • Kim IW; Department of Medical and Biological Sciences, The Catholic University of Korea, Bucheon, Gyeonggi-do, South Korea.
  • Youn H; R&D Research Center, SML Biopharm, Gwangmyeong, Gyeonggi-do, South Korea.
  • Keum G; Department of Medical and Biological Sciences, The Catholic University of Korea, Bucheon, Gyeonggi-do, South Korea.
  • Bang EK; Department of Medical and Biological Sciences, The Catholic University of Korea, Bucheon, Gyeonggi-do, South Korea.
  • Rhee JH; BK21 four Department of Biotechnology, The Catholic University of Korea, Bucheon, Gyeonggi-do, South Korea.
  • Lee SE; Department of Medical and Biological Sciences, The Catholic University of Korea, Bucheon, Gyeonggi-do, South Korea.
  • Nam JH; BK21 four Department of Biotechnology, The Catholic University of Korea, Bucheon, Gyeonggi-do, South Korea.
J Med Virol ; 95(12): e29309, 2023 12.
Article en En | MEDLINE | ID: mdl-38100632
ABSTRACT
The E6 and E7 proteins of specific subtypes of human papillomavirus (HPV), including HPV 16 and 18, are highly associated with cervical cancer as they modulate cell cycle regulation. The aim of this study was to investigate the potential antitumor effects of a messenger RNA-HPV therapeutic vaccine (mHTV) containing nononcogenic E6 and E7 proteins. To achieve this, C57BL/6j mice were injected with the vaccine via both intramuscular and subcutaneous routes, and the resulting effects were evaluated. mHTV immunization markedly induced robust T cell-mediated immune responses and significantly suppressed tumor growth in both subcutaneous and orthotopic tumor-implanted mouse model, with a significant infiltration of immune cells into tumor tissues. Tumor retransplantation at day 62 postprimary vaccination completely halted progression in all mHTV-treated mice. Furthermore, tumor expansion was significantly reduced upon TC-1 transplantation 160 days after the last immunization. Immunization of rhesus monkeys with mHTV elicited promising immune responses. The immunogenicity of mHTV in nonhuman primates provides strong evidence for clinical application against HPV-related cancers in humans. All data suggest that mHTV can be used as both a therapeutic and prophylactic vaccine.
Asunto(s)
Palabras clave
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Neoplasias del Cuello Uterino / Proteínas Oncogénicas Virales / Infecciones por Papillomavirus / Vacunas contra Papillomavirus Límite: Animals / Female / Humans Idioma: En Revista: J Med Virol Año: 2023 Tipo del documento: Article País de afiliación: Corea del Sur Pais de publicación: Estados Unidos
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Neoplasias del Cuello Uterino / Proteínas Oncogénicas Virales / Infecciones por Papillomavirus / Vacunas contra Papillomavirus Límite: Animals / Female / Humans Idioma: En Revista: J Med Virol Año: 2023 Tipo del documento: Article País de afiliación: Corea del Sur Pais de publicación: Estados Unidos